



Press Release

Friday, July 1, 2011



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR POLYMYXIN INJECTION

June 29, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Polymyxin B for injection, USP, an antibacterial drug, in 500,000 units per vial, latex-free glass vials

Polymyxin B sulfate is an antibacterial drug used in the treatment of infections of the urinary tract, meninges and bloodstream caused by susceptible strains of *Pseudomonas aeruginosa*. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of *Pseudomonas aeruginosa*.


According to 2010 IMS data, the U.S. market for Injectable Polymyxin B approximated USD 8 Million, with few approved players. As with all products in the Strides- Sagent JV, Polymyxin B features the Prevent IV Measures packaging and labelling designed to aid in the reduction of medication errors.

The product is expected to be launched in Q3 2011

Polymyxin is the third product approval for Sagent Strides LLC in 2011 and the eleventh approval under the Sagent-Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 66580111	Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Ajay Singh – 080 66580813 Mr. Kannan N - +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in

